Start here if you're new
what it is
Organogenesis sells wound-healing and tissue-repair products to help doctors close hard-to-heal wounds and support surgical recovery.
how it gets paid
Last year Organogenesis Hold made $564M in revenue.
why it's growing
Revenue grew 17.0% last year. That is the clean contrast. Sales were up 124% vs. prior year to $339M.
what just happened
Revenue reached $339M, but EPS fell to -$0.12.
At a glance
B balance sheet — gets the job done, barely
30/100 earnings predictability — expect surprises
37.2x trailing p/e — you're paying up for this one
5.1% return on capital — nothing to write home about
$0.13 fy2024 eps est
xvary composite: 54/100 — below average
What they do
Organogenesis sells wound-healing and tissue-repair products to help doctors close hard-to-heal wounds and support surgical recovery.
This is a portfolio business, not a one-product lottery ticket. Organogenesis sells across advanced wound care and surgery, and it has 869 employees pushing that product shelf into clinics and hospitals. The practical edge is durability: long-term debt is just $31M, or 8% of capital, so you are backing a company with more room to absorb shocks than a debt-heavy small-cap peer.
How they make money
$564M
annual revenue · their business grew +17.0% last year
total revenue
$564M
+17.0%
The products that matter
advanced wound care biologic
Affinity
inside a $172.6M segment
it sits inside the advanced wound care bucket, which posted $172.6M in revenue in the current source data. Products like this help explain how the company reached a 78% Q4 gross margin.
78% Q4 margin backdrop
surgical and sports medicine matrix
Novachor
inside a $391.4M segment
it sits inside the larger $391.4M surgical and sports medicine bucket in the current snapshot. That bucket matters because any reimbursement or mix pressure there flows straight into the guided 58%–60% gross margin range for 2026.
margin reset risk
Key numbers
$564M
ttm revenue
Revenue is bigger than the $340M market value. Translation: market cap → what the stock market says the company is worth → so what, you are paying about $0.60 for each $1 of trailing sales.
37.2x
trailing p/e
P/E → price-to-earnings ratio → so what, the stock is not cheap if you judge it on the FY2024 EPS estimate of $0.13.
8.0%
operating margin
Operating margin → the slice left after running the business → so what, this is a thin profit buffer for a company facing reimbursement pressure.
$31M
long-term debt
Long-term debt is just 8% of capital. Translation: capital structure → how the business is funded → so what, the balance sheet gives you time if operations wobble.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 2 — safer than 80% of stocks
- price stability 5 / 100
- long-term debt $31M (8% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ORGO right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Revenue reached $339M, but EPS fell to -$0.12.
That is the clean contrast. Sales were up 124% vs. prior year to $339M, while profitability moved the other way with a gross margin of 18.6%. There is also a data mismatch: Value Line's 2024 quarterly EPS path looks steadier than this latest EDGAR quarter, and Yahoo shows last reported EPS of $0.11.
$339M
revenue
$0.12
eps
18.6%
gross margin
the number that mattered
The 18.6% gross margin mattered most because margin → money left after making the product → so what, weak margin makes the n/a revenue jump much less impressive.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
The main threat is CMS reimbursement pressure on wound-care economics. This is specific, already in guidance, and large enough to reset both revenue and margin at the same time.
med
CMS reimbursement reset
Management tied its 2026 outlook to CMS policy changes. That makes reimbursement the operating variable, not a side note.
Impact: the current guide implies $141M–$214M less revenue versus the $482M source-data baseline.
med
Gross margin compression
Q4 gross margin was 78%, but the 2026 guide is 58%–60%. Specialty-medtech multiples do not hold up well when the specialty economics disappear.
Impact: an 18–20 point margin reset would shrink the profit cushion that made the business look premium in the first place.
med
Earnings and stock volatility
A 30 / 100 earnings predictability score and 5 / 100 price stability score tell you the market expects uneven numbers and reacts sharply when it gets them.
Impact: even small misses can move the stock hard when confidence is already thin.
med
Legal overhang
The snapshot includes a securities-fraud investigation notice from Pomerantz LLP dated Feb. 27, 2026. The legal process may go nowhere, but it still adds friction around an already fragile story.
Impact: harder sentiment, potential legal expense, and one more reason investors demand a lower multiple.
This is a reimbursement-sensitive business where the current guide already points to lower sales and much lower margin. If the guide proves accurate, the valuation will have to lean on a recovery story, not current fundamentals.
source: institutional data · regulatory filings · risk analysis
Pay attention to
reimbursement
CMS policy language
The entire story runs through reimbursement now. If management starts narrowing the impact range, that is the first sign the revenue damage could land closer to 25% than 38%.
margin
gross margin versus the 58%–60% guide
Q4 printed 78%. If reported margins start tracking near 60%, the premium-product narrative weakens fast. If they hold materially above that range, the stock gets a better defense.
calendar
next earnings update
The next quarter matters more than usual because investors need proof that the revenue and margin reset is either real, or overstated. Guidance quality is the event.
trading
whether volatility cools down
A 5 / 100 price stability score means confidence is thin. If the stock stays disorderly after management updates the reimbursement outlook, the market is telling you uncertainty is still winning.
Analyst rankings
earnings predictability
30 / 100
Low predictability. In human-speak, analysts do not trust this business to produce smooth quarterly numbers.
risk rank
2
This score says the company is financially safer than many stocks. It does not mean the earnings story is safe.
price stability
5 / 100
The stock has been unstable. You are buying into a setup where sentiment can move faster than fundamentals.
source: institutional data
Institutional activity
institutional ownership data for ORGO is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$5
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive